PDGFRB and colorectal carcinoma: The mechanism of cytotoxicity, through broad kinase, targets several crucial parts of CRC development, such as angiogenesis (by inhibiting VEGFR1, −2, −3, TIE2, PDGFR, and FGFR1 and −2), proliferation (by inhibiting c-KIT, RAF1, BRAF, and RET), metastasis (by inhibiting VEGFR2 and −3, and PDGFR), and immunosuppression (by inhibiting CSF1R) [11].